Jackie Syrop


Amazon, Berkshire Hathaway, and JPMorgan Chase to Form Healthcare Company

January 30, 2018

Jeff Bezos, Amazon’s founder and CEO, said that reducing healthcare’s burden on the economy while improving outcomes for employees and their families would be worth the effort, and the 3 companies had the talented experts with fresh approaches and a long-term orientation that will be key to success.

Do Inadequate Storage Practices Play a Role in Loss of Response to Subcutaneous Biologic Agents?

January 29, 2018

A recent study, set in the Netherlands, sought to assess patients’ attitudes about redistributing unused, subcutaneously administered biologic drugs, which could allow potential cost savings for the health system. However, the study unexpectedly found alarming storage inconsistencies and patient nonadherence to storage guidelines for these drugs.

Drug Costs, Healthcare Spending Grow Over Time for Medicaid Expansion Populations

January 27, 2018

Healthcare spending for the Medicaid expansion population increased steadily over time for beneficiaries who remained enrolled in Medicaid, according to a new analysis from Avalere Health. The analysis also found that spending for prescription drugs increased over the study period, with pharmacy costs (excluding prescription drug claims for hepatitis C treatments) almost doubling over the 2.5-year time period during which the cohort was tracked

Pfizer's PF-05280586 Shows Equivalence to Reference Rituximab in Comparative Study

January 24, 2018

Pfizer announced today that PF-05280586, the company’s proposed biosimilar to reference rituximab (Rituxan, MabThera), has been shown to be equivalent to the reference in overall response rate for the first-line treatment of patients with CD20-positive, low tumor burden follicular lymphoma.

Similar Safety, Efficacy, Immunogenicity Shown for Admelog and Reference Humalog

January 23, 2018

SAR342434, or Admelog, a follow-on of insulin lispro (Humalog), showed similar efficacy, safety, and immunogenicity to its reference in patients with type 2 diabetes who also used insulin glargine (Lantus) as basal insulin, according to the results of the SORELLA-2 study, published in the January 2018 issue of Diabetes Technology & Therapeutics.

Study of RA Remission Predictors Supports Treat-to-Target Approach to Combination Etanercept Therapy

January 22, 2018

Targeting sustained and stringently defined clinical remission in patients with moderately active rheumatoid arthritis (RA) receiving full-dose combination therapy with etanercept plus methotrexate before considering dose or regimen changes may help improve the likelihood that patients will remain in clinical remission 1 year after the changes are made.

Group of US Hospitals to Form Nonprofit Generic Drug Company

January 19, 2018

Four hospital groups, representing approximately 450 US hospitals, are planning to create their own nonprofit generic drug company in a bold move designed to address generic drug shortages and high prices affecting their hospitals.

Can Anti-TNF Therapies Treat Insulin Resistance and Type 2 Diabetes?

January 19, 2018

Antagonism of tumor necrosis factor-alpha (TNF-alpha) may be a good treatment strategy to counter the deleterious effects of TNF-alpha on the development of insulin resistance and the pathogenesis of type 2 diabetes.

Review Argues That Same Safety, Efficacy Can Be Expected From Biologics, Biosimilars

January 18, 2018

In an expert review, the authors provide transparency about biosimilar production, approvals, risk, and benefits to help improve confidence that the same safety and efficacy can be expected from biologics and their biosimilars.

Obinutuzumab a Promising Candidate for Plant-Produced Biosimilar

January 16, 2018

Researchers based in the Republic of Korea have published data suggesting that they were able to produce a promising biosimilar obinutuzumab candidate from the plant Nicotiana benthamiana L. that is equivalent to obinutuzumab produced in glyco-engineered Chinese hamster ovary cells.